Safety
Scope & Guideline
Innovating safety practices for a healthier environment.
Introduction
Aims and Scopes
- Pharmacovigilance Methodologies:
The journal emphasizes innovative methodologies in pharmacovigilance, including signal detection, disproportionality analysis, and the use of artificial intelligence and machine learning in analyzing adverse event data. - Drug Safety in Special Populations:
A core focus is the safety of drugs in vulnerable populations such as pregnant women, children, and the elderly, addressing specific risks and pharmacological considerations unique to these groups. - Real-World Evidence and Data Utilization:
The journal promotes the use of real-world data and observational studies to evaluate drug safety, efficacy, and the impact of medications on diverse populations. - Regulatory and Policy Frameworks:
Research published often examines the implications of regulatory changes, risk communication, and the effectiveness of risk minimization strategies in ensuring drug safety. - Emerging Therapies and Vaccines:
The journal explores the safety profiles of novel therapeutics and vaccines, particularly in the context of recent global health challenges, such as the COVID-19 pandemic. - Pharmacogenomics and Personalized Medicine:
There is a growing interest in the intersection of pharmacogenomics and pharmacovigilance, focusing on how genetic factors influence drug safety and efficacy.
Trending and Emerging
- Artificial Intelligence and Machine Learning:
There is a significant increase in research exploring the application of AI and machine learning for drug safety signal detection and adverse event reporting, highlighting the transformative potential of these technologies. - Patient-Centered Pharmacovigilance:
Emerging themes focus on patient involvement in pharmacovigilance processes, emphasizing the importance of patient-reported outcomes and experiences in enhancing drug safety monitoring. - Integration of Real-World Data:
The use of real-world data sources, including electronic health records and social media, is trending, enabling more comprehensive analyses of drug safety in diverse populations. - Safety of Biologics and Novel Therapies:
The journal is increasingly publishing studies on the safety profiles of biologics and novel therapies, particularly in the context of personalized medicine and complex treatment regimens. - Global Pharmacovigilance Strategies:
Research on collaborative global strategies for pharmacovigilance is emerging, reflecting the need for coordinated efforts to address drug safety on an international scale. - Risk Communication and Management:
There is a growing focus on effective risk communication strategies and their role in managing public perceptions of drug safety, particularly during health crises like the COVID-19 pandemic.
Declining or Waning
- Traditional Pharmacovigilance Approaches:
There is a noticeable decrease in studies solely focused on traditional pharmacovigilance methods, as newer technologies and data analysis techniques gain traction. - Single-Country Studies:
Research that focuses exclusively on drug safety within a single country is less common, with a shift towards multinational studies that provide a broader perspective on drug safety. - Generalized Reporting Practices:
Publications that discuss generalized reporting practices without specific recommendations or frameworks are becoming less frequent, as the field moves towards more targeted and evidence-based approaches. - Historical Drug Safety Evaluations:
There is a waning interest in retrospective evaluations of older drugs that do not incorporate current methodologies or technologies, as the field prioritizes research that can inform modern clinical practices. - Pharmacovigilance in Isolation:
Research focusing on pharmacovigilance in isolation from other healthcare systems and processes is declining, with a trend towards integrated approaches that consider broader healthcare implications.
Similar Journals
PHARMAZIE
Fostering excellence in pharmaceutical scholarship.PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.
Therapeutic Advances in Drug Safety
Bridging Pharmacological Innovation and Clinical ExcellenceTherapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Enhancing lives with cutting-edge cardiovascular pharmacological insights.JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.
JOURNAL OF CLINICAL PHARMACOLOGY
Innovating Insights in Clinical PharmacologyWelcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.
Therapeutics and Clinical Risk Management
Advancing medication safety through innovative research.Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.
DRUG SAFETY
Leading the Charge in Drug Safety InnovationDRUG SAFETY is a premier academic journal published by ADIS INT LTD, dedicated to the critical field of pharmacology and toxicology. Since its inception in 1990, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals by providing high-quality, peer-reviewed articles that inform and advance the understanding of drug safety and efficacy. With an impressive impact factor and its current Q1 categorization in Pharmacology across various sub-disciplines, DRUG SAFETY is ranked among the top journals in its field, reflecting its commitment to excellence in scientific research. The journal features a diverse range of studies, reviews, and case reports addressing contemporary issues in drug safety, making it an invaluable tool for academia and industry alike. Although it is not an open-access journal, the content is accessible to subscribers and institutions, ensuring that essential findings in drug safety reach the widest audience possible. As the field evolves, DRUG SAFETY remains at the forefront, driving innovation and improving regulatory practices worldwide.
Journal of Young Pharmacists
Transforming Ideas into Impactful ResearchJournal of Young Pharmacists is a distinguished peer-reviewed journal published by INPHARM ASSOCIATION in collaboration with PHCOG NET. With an ISSN of 0975-1483 and an E-ISSN of 0975-1505, this journal serves as a vital platform for disseminating pioneering research in the field of pharmacology and toxicology. Although coverage in Scopus was discontinued in 2018, the journal continues to be important in educating future pharmacists and advancing the discipline, evident from its ranking in the 29th percentile among general pharmacology journals. The Journal of Young Pharmacists seeks to bridge the gap between theoretical knowledge and practical application, encouraging young researchers, professionals, and students to contribute their insights and findings. The journal emphasizes innovative approaches and contemporary issues relevant to the pharmaceutical sciences, making it an invaluable resource for anyone involved in this dynamic field.
Journal of Health and Safety at Work
Innovating practices for a safer work environment.The Journal of Health and Safety at Work, published by the Iranian Occupational Health Association, is a vital resource for researchers, professionals, and students engaged in the fields of occupational health, safety, and environmental management. With an ISSN of 2251-807X and E-ISSN 2383-2088, this Open Access journal has been dedicated to disseminating knowledge since 2012, ensuring that critical research is accessible to a global audience. The journal’s scope encompasses a diverse range of topics including human factors and ergonomics, safety research, and public health, with a focus on enhancing workplace safety and environmental standards. Although currently positioned in the Q4 category across various disciplines within safety and health research, the journal offers a unique platform for emerging studies and innovative practices, making it a significant contributor to the discourse in these fields. The journal's commitment to open access aligns with the growing trend of transparent scholarship, thus facilitating the sharing of vital insights to improve workplace health and safety outcomes. Researchers aiming to publish groundbreaking studies in this pivotal area will find the Journal of Health and Safety at Work an indispensable avenue for advancing knowledge and fostering professional collaboration.
Drug Healthcare and Patient Safety
Empowering research to enhance patient care.Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.
JOURNAL OF PHARMACY TECHNOLOGY
Pioneering advancements in pharmaceutical science since 1989.JOURNAL OF PHARMACY TECHNOLOGY is a premier publication in the field of Pharmaceutical Science, established in 1989 and published by SAGE PUBLICATIONS INC. This journal serves as an essential resource for professionals, researchers, and students dedicated to the advancements in pharmacy technology and the application of innovative solutions in pharmaceutical practices. With an ISSN of 8755-1225 and an E-ISSN of 1549-4810, the journal provides a rigorous peer-reviewed platform for disseminating cutting-edge research and case studies. As of 2023, it is ranked Q3 in the Scopus categories of Pharmacology, Toxicology, and Pharmaceutics, highlighting its relevance in the field. Although it currently does not offer an Open Access option, JOURNAL OF PHARMACY TECHNOLOGY aims to remain a critical avenue for scholarly communication and knowledge dissemination among practitioners in the pharmaceutical sector, ensuring they stay informed of the latest trends and findings that impact their work.